Drug Controller General of India approves commercial launch of COVID-19 test 'FELUDA'
National
- The Tata Clustered Regularly Interspaced Short Palindromic Repeats, CRISPR test, powered by CSIR-Institute of Genomics and Integrative Biology (IGIB) FELUDA has received regulatory approvals from the Drug Controller General of India for commercial launch.
- As per the Indian Council of Medical Research (ICMR) guidelines, the test has met high quality benchmarks with 96 per cent sensitivity and 98 per cent specificity for detecting the Novel Corona virus.
- This test uses an indigenously developed, cutting-edge CRISPR technology for detection of the genomic sequence of SARS-CoV-2 virus.
- CRISPR is a genome editing technology to diagnosing diseases.
- The Tata CRISPR test is the world’s first diagnostic test to deploy a specially adapted Cas9 protein to successfully detect the virus causing COVID-19.
Source: AIR
Related General Knowledge
Drugs Controller General of India
- Drugs Controller General of India is a department of the Central Drugs Standard Control Organization of the Government of India.
- It is responsible for approval of licences of specified categories of drugs such as blood and blood products, IV fluids, vaccines, and sera in India.
- Officeholder: Dr. V. G. Somani
- Headquarters location: New Delhi
Indian Council of Medical Research
- The Indian Council of Medical Research, the apex body in India for the formulation, coordination and promotion of biomedical research, is one of the oldest and largest medical research bodies in the world.
- Headquarters: New Delhi
- Director General: Dr. Balram Bhargava
- Founded: 1911